INTRODUCTION AND OBJECTIVES:
In the present study we investigate the collagenic extracellular reactive matrix in a series of prostate cancer biopsy specimens and benign prostatic hyperplasia (BPH) following transurethral resection of the prostate (TURP). Particularly the study focused on the type of collagen composition and its spatial organization.
METHODS: 60 prostate specimens were investigated, 50 prostate carcinoma and 15 BPH. The samples were fixed in 10% formaldehyde and paraffin-embedded. Two-micrometer thick sections were cut and stained with picric acid-sirius red staining to distinguish type I and III collagen using a polarized light microscopy. The ratios of collagen I/III were automatically evaluated using a computer-aided image analysis system. The spatial organization was evaluated on unstained tissue sections by combining a multi-photon microscopy and an open-source MATLAB software framework that includes two separate but linked packages 00 CurveAlign 00 and 00 CT-FIRE 00 . All of the data were analyzed using Statistica software (StatSoft, Inc., Tulsa, OK, USA) and GraphPad Prism 5 (San Diego, California, USA).
RESULTS: By observing the stained sections with Picro-Sirius Red we found different conformations of the collagenic extracellular matrix. Collagen matrix is characterized by a set of highly irregular fragments with different size, size and roughness: tumor microenvironment consists of thin collagen fibers while dense plaques have been observed in the microenvironment that characterizes BPH . Additionally, we found that in BPH type III collagen is less represented if compared to the low and high-grade tumoral tissues. A statistically significant difference was identified between BPH and biopsies of patients with low-grade tumor and in whose fragment no neoplastic cells were observed (p<0.001). In addition, the alignment of collagen fibers is much more pronounced in biopsy of prostate cancer patients than in tissues of patients with BPH.
CONCLUSIONS: Collagen type (type I versus type III) composition and its spatial organization i.e. alignment is different when evaluated in tumoral versus inflammatory state. Given the dynamical process of tissue matrix remodeling, our findings first demonstrated that stromal collagen alignment might provide additional, clinically-relevant information about prostate cancer and underscores the importance of stroma-cancer interactions.
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MP64-18 THE ANALYSIS OF EXPRESSION AND MOLECULAR MECHANISM FOR VASOHIBIN-2 IN PROSTATE CANCER
Yasumasa Miyazaki*, Takeo Kosaka, Shuji Mikami, Hiroshi Hongo, Yota Yasumizu, Nobuyuki Tanaka, Eiji Kikuchi, Tokyo, Japan; Yasufumi Sato, Miyagi, Japan; Mototsugu Oya, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Vasohibin-2 (VASH2) which is an intrinsic angiogenic molecule specifically expressed in activated vascular endothelial cells (ECs). Previous studies found that the expression of VASH2 was restricted to ECs and tumor cells. Although VASH2 promoting the angiogenesis in several cancers have been investigated, it has not been fully characterized yet that the VASH2 reflects the activity of tumor and the predictor of progression in prostate cancer (Pca). The aim of this study was to address the prognostic value of VASH2 expression in patients with Pca and to analyze the molecular mechanism of the treatment by targeting VASH2 in Pca.
METHODS: We retrospectively analyzed the clinical records of 206 patients with localized Pca performed radical prostatectomy and immunohistochemically analyzed the expression of VASH2. The expression of VASH2 was observed to ECs of microvessels in the tumor stroma and Pca cells. We immunohistochemically examined the tumor cells with VASH2 as VASH2 score and the microvessels with activated ECs as VASH2 density. We analyzed the expression of VASH2 in human umbilical vein ECs (HUVEC) and Pca cell lines. Gene expression of these cells treated with anti-VASH2 antibody (V2-ab) was evaluated by microarray analysis and real-time PCR. We analyzed murine xenograft PCa model treated with V2-ab.
RESULTS: The 5-year PSA recurrence-free survival rates were significantly worse in high VASH2 score (78.9%) than in low VASH2 score (90.9%) (P< 0.05). Multivariate analyses revealed that high VASH2 score was an independent prognostic indicator of PSA recurrence (P¼ 0.006, HR¼ 2.68), as well as other standard prognostic factors including preoperative PSA and pathological T stage. Microarray analysis revealed dynamic change of gene expression in EpithelialMesenchymal Transition (EMT) related signaling of TGF beta related pathway in HUVEC and Pca cells when treated with V2-ab. Real-time PCR revealed suppression of gene expression associated with EMT, cancer proliferation and angiogenesis in Pca cells treated with V2-ab. In vivo assay, we examined time course changes in Pca tumor growth in mice. The average tumor size in V2-Ab treatment group was significantly decreased than that in the control group.
CONCLUSIONS: VASH2 represents a clinically relevant predictor of patient prognosis in PCa. The results suggest that VASH2 could become a new biomarker and provide additional prognostic information in patients with PCa. The treatment to suppress the EMT, cancer proliferation, and angiogenesis by V2-ab suggests that VASH2 could become a new therapeutic target in patients with PCa.
INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) risk stratification is based on tumour size, PSA level and Gleason Score, but it remains imprecise. Current research focuses on the discovery of novel biomarkers to improve the identification of patients at risk of tumour progression. The purpose of this study was to develop a gene expression signature for predicting tumour progression after radical prostatectomy.
METHODS: Retrospective study which includes 188 PCa patients who attended at our department between 2000 and 2007. Formalin-fixed paraffin embedded PCa tissue samples were collected. Global gene expression patterns were analysed in 21 selected samples from 7 localized, 6 locally advanced, and 8 metastatic PCa patients using Illumina microarrays. Expression levels of 45 genes selected from microarray data and literature were studied by quantitative PCR in an independent series of 167 patients who underwent radical prostatectomy for clinically localized PCa and with 10 years follow-up. Biochemical recurrence (BCR) was defined as 2 consecutive PSA values 0.2ng/mL or salvage treatment 6 months after prostatectomy. Univariate and multivariate logistic regression analysis was used to identify individual predictors of BCR and metastatic recurrence. Kaplan Meier curves were used to discriminate two groups of localized PCa patients with different probability of progression. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e857
